Retrospective analysis to evaluate the efficacy and the safety of Bevacizumab in the treatment of recurrent malignant gliomas

Retrospective analysis to evaluate the efficacy and the safety of Bevacizumab in the treatment of recurrent malignant gliomas

Abstract Background There is no consensus therapy recommended for recurrent malignant gliomas (MGs). In 2009, Bevacizumab (BEV) was approved by the FDA as single-agent for recurrent glioblastoma (GBM). The aim of this retrospective study was to evaluate the efficacy and the safety of BEV alone or in...

Full description

Bibliographic Details
Main Authors: Arsela Prelaj, Sara Elena Rebuzzi, Maurizio Salvati, Silvia Pecorari, Chiara Pozzi, Carmela Fusto, Carla Ferrara, Silverio Tomao, Vincenzo Bianco
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Translational Medicine Communications
Subjects:
Bevacizumab
Recurrent glioblastoma
Recurrent malignant glioma
Fotemustine
Retrospective study
Online Access:http://link.springer.com/article/10.1186/s41231-018-0023-2

Internet

http://link.springer.com/article/10.1186/s41231-018-0023-2

Similar Items